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Background: Airway smooth muscle (ASM) from asthmatics is in a hyperproliferative state and releases more cytokines
than healthy individuals.
Results: Inhibition of BET bromodomains reduces ASM proliferation and cytokine release by reducing Brd4 binding to the
promoter regions of IL-6 and CXCL8.
Conclusion: BET bromodomain mimics inhibit aberrant ASM proliferation and inflammation in asthmatic patients.
Significance: These compounds may reduce airway remodeling in asthma.
Airway smooth muscle (ASM) mass is increased in asthma,
and ASM cells from patients with asthma are hyperproliferative
and releasemore IL-6 and CXCL8. The BET (bromo- and extra-
terminal) family of proteins (Brd2, Brd3, and Brd4) govern the
assembly of histone acetylation-dependent chromatin com-
plexes.We have examined whether they modulate proliferation
and cytokine expression in asthmatic ASM cells by studying the
effect of BET bromodomain mimics JQ1/SGCBD01 and
I-BET762. ASM cells from healthy individuals and nonsevere
and severe asthmatics were pretreated with JQ1/SGCBD01 and
I-BET762 prior to stimulation with FCS and TGF-. Prolifera-
tion was measured by BrdU incorporation. IL-6 and CXCL8
release was measured by ELISA, and mRNA expression was
measured by quantitative RT-PCR. ChIP using a specific anti-
Brd4 antibody and PCR primers directed against the transcrip-
tional start site of IL-6 and CXCL8 gene promoters was per-
formed. Neither JQ1/SGCBD01 nor I-BET762 had any effect on
ASM cell viability. JQ1/SGCBD01 and I-BET762 inhibited
FCSTGF--induced ASM cell proliferation and IL-6 and
CXCL8 release in healthy individuals (> 30 nM) and in non-
severe and severe asthma patients (>100 nM), with the latter
requiring higher concentrations of these mimics. JQ1/
SGCBD01 reduced Brd4 binding to IL8 and IL6 promoters
induced by FCSTGF-.Mimics of BETbromodomains inhibit
aberrant ASM cell proliferation and inflammation with lesser
efficiency in those from asthmatic patients. They may be effec-
tive in reducing airway remodeling in asthma.
Chronic airflow obstruction and airway inflammation and
remodeling are fundamental characteristics of asthma (1). Air-
way smooth muscle (ASM)4 mass is increased in asthma
because of enhancedASMhyperplasia and hypertrophy, result-
ing in subepithelial fibrosis and narrowing of the airways. ASM
cells also play a key role in the chronic inflammatory response
in the airways of asthmatics through the expression of cyto-
kines, growth factors, and proteases (2), which can induce phe-
notypic changes in ASM (3). TGF- promotes ASM cell prolif-
eration and size (4) and also induces the release of IL-6 and
CXCL8, which are involved in many inflammatory effects
including ASM-induced mast cell activation and the release of
CCL11 and vascular endothelial growth factor (5–7).
Severe asthma is characterized by the persistence of symp-
toms despite optimal therapy with corticosteroids (8, 9). ASM
mass and subepithelial fibrosis in the bronchial airways is
increased in severe asthma patients when compared with non-
severe asthma patients (10, 11). This may be a consequence of
the enhanced proliferation of ASM cells from patients with
severe asthma compared with those from nonsevere asthma
following stimulationwith FCS andTGF- (12–14). In addition
to an abnormal proliferative response, these cells also demon-
strate relative corticosteroid insensitivity (15), and because
these responses are seen after up to five cell culture passages, it
is likely that they are due to altered or rewired intracellular
signaling pathways or to epigenetic mechanisms (16). Reduced
responses of blood monocytes and alveolar macrophages to
corticosteroids representing corticosteroid insensitivity have
also been reported in patients with severe asthma (17, 18).
Histone modifications such as acetylation, phosphorylation,
andmethylation are regulated in a temporal and spatialmanner
to control chromatin structure under a “histone code or lan-
guage” (19, 20). Enhanced histone acetylation is associated with
altered cellular function including the increased expression of
inflammatory genes. Acetylated histones are detected by pro-
teins that contain a bromodomain motif, such as the BET (bro-
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mo- and extra-terminal) family members that include Brd2,
Brd3, and Brd4 and that govern the assembly of histone acety-
lation-dependent chromatin complexes. This epigenetic tag is
linked to control RNA polymerase II activity via recruitment of
transcriptional activators such as pTEFb (21, 22). BET family
members such as Brd4 have been implicated in the regulation of
NF-B-induced inflammatory gene expression in monocytes
and macrophages through recognition of acetylated histone
tags (23, 24). BET proteins can also associate with c-Myc to
regulate cell proliferation (24).
We hypothesized that BETproteins play an important role in
the regulation of proliferation and release of pro-inflammatory
cytokines in ASM cells from patients with asthma. BETmimics
JQ1/SGCBD01 and I-BET762 that prevent the association of
bromodomain-containing proteins with acetylated lysines have
recently been developed (23, 25). These mimics affect prolifer-
ation and the expression of some inflammatory genes inmurine
and human cell types (23, 25, 26), but this is the first time that
effects have been reported in these primary ASM cells from
patients with asthma. We used these inhibitors to investigate
the role of BET proteins in the regulation of TGF--induced
proliferation and inflammation of ASM obtained from patients
with different severities of asthma. Our results show that inhi-
bition of BET bromodomains can reduce both aberrant ASM
cell proliferation and expression of cytokines from patients
with severe asthma by reducing Brd4 binding to the promoter
regions of IL8 and IL6 genes.
MATERIALS ANDMETHODS
Patient Recruitment—Subjectswere defined as nonasthmatic
on the basis of absent history of asthma and a normal respon-
siveness of the airways to the constrictor effect of metacholine
measured as PC20  16 mg/ml and nonsevere or severe asth-
matic according to American Thoracic Society workshop defi-
nition of severe refractory asthma (27). Current smokers and
former smokers with a greater than 5 pack-year history were
excluded. Subject characteristics are shown in Table 1. Bron-
chial biopsies were obtained from segmental and subsegmental
airways of the right lower lobe by fiberoptic bronchoscopy as
described previously (11). The study conformed to the Decla-
ration of Helsinki and was approved by the ethics committee of
the Royal Brompton Hospital. Written informed consent was
obtained from each subject.
ASMCell Culture and Stimulation—ASM cells were isolated
and cultured from bronchial biopsies as previously described
(4, 15). At confluence, ASMcell cultures exhibited a typical “hill
and valley” appearance. Human airway smooth muscle cells at
passages 3–4 from nine different donors were used. Prior to
treatment, ASM cells were plated onto 96-well plates for mea-
surement of DNA synthesis and cytokine release, and 6-well
plates for RNA and protein extraction. Cells were growth-ar-
rested by FCS deprivation for 24 h in DMEM supplemented
with sodiumpyruvate (1mM), L-glutamine (2mM), nonessential
amino acids (1:100), penicillin (100 units/ml)/streptomycin
(100 g/ml), amphotericin B (1.5 g/ml), and bovine serum
albumin (0.1%) (All from Sigma-Aldrich).
Cells were pretreatedwith JQ1/SGCBD01 (denoted as JQ1)
(3–1000 nM), its enantiomer (JQ1) (3–1000 nM), or I-BET762
(3–1000 nM) (all from Tocris, Bristol, UK) or a c-Myc inhibitor
(25–150 M) (10058-F4; Sigma-Aldrich) for 1 h before being
stimulated with 2.5% FCS TGF- (1 ng/ml) (Sigma-Aldrich)
at 8 days. We have previously demonstrated that this is the
optimum time point to observe differences in phenotype
between these ASM cells (4). Cell proliferation was measured
by the cell proliferation ELISA BrdU kit (Roche Diagnostics) an
assay comparablewithmeasuring cell numbers as confirmed by
flow cytometry (4, 28). Supernatants were removed, and IL-6
and CXCL8 levels were determined by DuoSet ELISA (R&D
Systems, Abingdon, UK). IL-6 and CXCL8 levels were normal-
ized to cell numbers, by dividing by the fold-change as mea-
sured by the BrdU assay. Cell viability was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (29).
Transfection with siRNAs to Target Brd4 and c-MYC—ASM
cells were transfected as previously described (4). Brd4 and
c-MYC siRNAwere obtained from (Thermo Scientific, Epsom,
UK). Control siRNA was obtained from Ambion/Applied Bio-
systems (Paisley, UK). Transfected cells were plated into
96-well plates and left to adhere overnight before being serum
starved for 6 h before stimulation with 2.5% FCS and 1 ng/ml
TGF- for 8 days.
mRNA Expression—IL6, IL8, p21WAF1, and p27kip1 mRNA
expression levels were measured as previously described (4,
30–32). In brief, total RNA was isolated using the RNeasy mini
kit (Qiagen), and mRNA expression levels were determined
using semiquantitative two-step RT-PCR using Assay on
Demand primer/probe sets obtained from Applied Biosystems
at 24 h. We have previously demonstrated that this is the opti-
mum time point to observe differences in mRNA expression
between these ASM cells (4).
Chromatin Immunoprecipitation Analysis—ChIP analysis
was carried using theMagnaChIPTMA/G chromatin immuno-
precipitation kit following the manufacturer’s instructions
(Merck Millipore, Watford, UK). In brief, ASM cells were
grown in culture and treated as described above. Following
stimulation the cells were formalin-fixed. The cells were soni-
cated to shear DNA (5 15 s at 40% amplitude) to200–1000
bp in length. Brd4 and c-Mycwere immunoprecipitated using 1
TABLE 1
Clinical characteristics of subjects
The data are shown as means  S.E. BDP, beclomethasone dipropionate; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; PC20, provocative
concentration of methacholine causing a 20% fall in FEV1; NA, not available; CS,
corticosteroid.
No
asthma
Nonsevere
asthma
Severe
asthma
n 9 9 9
Age (years) 36.4 12.7 42.4 16.2 40.9 11
Sex (male/female) 7/2 6/4 3/6
Duration of asthma (years) NA 22.2 16.8 25.6 13.2
Atopy (n)a 0 8 7
Inhaled CS (g of BDP
equivalent)
0 0 1688.9 176.4
On daily oral CS (n) 0 0 3
FEV1 (liters) 4.0 0.5 2.8 0.7 2.7 0.8
FEV1 (% predicted) 104.2 7.3 84.7 12.3 84.5 18.3
-Agonist reversibility (%)b NA 12.3 11.9 19.5 14.6
PC20 (mg/ml) 16 0.69 0.64 0.20 0.39
a Defined as positive skin prick tests to one or more common aeroallergens.
bMeasured as percent increase in FEV1 after 400 g of salbutamol.
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g of antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
After reverse cross-linking, the DNA was purified and quanti-
tative PCR carried out using SybrGreen (Qiagen) and the fol-
lowing primers: pCXCL8 forward, 5-GGGCCATCAGTTGC-
AAATC-3; pCXCL8 reverse, 5-TCCTTCCGGTGGTTTC-
TTC-3; pIL6 forward, 5-CAAGCCTGGGATTATGAAGA-
AGG-3; and pIL6 reverse, 5-AGCACTGGCAGCACA-
AGGCAAAC-3. TheamountofDNArecoveredbyChIPwasnor-
malized to an input control. IgG isotype antibodies (providedbyMil-
lipore)were used as a negative control for theChIP assay.
Data Analysis—The data were analyzed using GraphPad
Prism version 5.03 (GraphPad Software, San Diego, CA). The
data were not normally distributed (as assessed by the Kolm-
ogorov-Smirnov test), and groups were compared using the
Dunn’s nonparametric test. Significance was defined as a p 	
0.05.
RESULTS
Effect of JQ1/SGCBD01 on FCSTGF--induced ASM
Proliferation—As previously reported, there was no difference
in baseline proliferation rate between the cells from the three
subject groups (4). Pretreatment of cells from healthy subjects
with JQ1 (30–1000 nM) inhibited FCSTGF--induced prolif-
eration in a concentration-dependentmanner reachingamaximal
effect of 43.3 26.5% (p	 0.001) at 1000 nM (Fig. 1A). However,
therewas a reduced sensitivity to JQ1 inASMcells fromboth the
nonsevere and severe asthmatic patients comparedwith that seen
inASMcells fromhealthy subjects in thatonly thehighest concen-
tration of JQ1 (1000 nM) reduced cell proliferation (p 	 0.001)
(Fig. 1A). In contrast, the negative enantiomer, JQ1, had no sig-
nificanteffectonproliferationofASMcells fromanypatientgroup
(Fig. 1B). In addition, neither JQ1nor JQ1 showedany effect on
ASM cell viability at any concentration tested (data not shown).
Effect of JQ1/SGCBD01 on FCSTGF--induced IL-6 and
CXCL8 Release—Pretreatment of cells from healthy subjects
with JQ1 (30–1000 nM) inhibited FCSTGF--induced IL-6
release in a concentration-dependent manner by up to 35.2 
7.8% at 1000 nM in ASM cells from healthy individuals (p 	
0.001; Fig. 1C). Although the asthmatic group appears to show
reduced sensitivity and higher maximum effect of inhibitors,
this is because the initial increases in both proliferation and
cytokine release from the different patient subsets were nor-
malized to 100%.
FIGURE 1. JQ1/SGCBD01, but not its negative enantiomer (JQ1), suppresses FCS and TGF--induced cell proliferation and cytokine release. A–F,
concentration-dependent effect of JQ1/JQ1 on FCS (2.5%) and TGF- (1 ng/ml)-induced cellular proliferation (A and B), IL-6 release (C and D), and CXCL8
release (E and F) after 8 days. Points represent means S.E. from ASM cells from nine healthy (*), nonsevere asthma (#), and severe asthma (‚) subjects.
*, p	 0.05; ***/###/, p	 0.001 compared with FCSTGF--stimulated cells.
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Similar to the results reported for proliferation, cells from
patients with severe and nonsevere asthma had a reduced sen-
sitivity to JQ1 with a significant repression of IL-6 release
observed at 100–1000 nM of JQ1 (p 	 0.001; Fig. 1C). The
negative enantiomer, JQ1, had no effect upon IL-6 release
(Fig. 1D).
Although there was a concentration-dependent inhibition of
FCSTGF--induced CXCL8 release from cells from all
groups, the effect of JQ1 upon CXCL8 release was different
from that seen with IL-6 release. Although 10 nM JQ1 was
sufficient to inhibit CXCL8 release from ASM cells isolated
from healthy individuals (p 	 0.001), 100–1000 nM JQ1 was
required to inhibit CXCL8 release from the nonsevere asth-
matic ASM cells (p 	 0.001), and only the highest concentra-
tions of JQ1 (300–1000 nM) inhibitedCXCL8 release from the
severe asthmatic ASM cells (p 	 0.001) (Fig. 1E). No effect of
the negative enantiomer, JQ1, on CXCL8 release was
observed (Fig. 1F).
Effect of I-BET762 on FCSTGF--induced ASM Prolifera-
tion and Inflammation—We observed effects similar to those
with JQ1with the structurally distinct BETmimic, I-BET762.
I-BET762 (30–1000 nM) inhibited FCSTGF--induced pro-
liferation by100% in ASM cells from healthy individuals (p	
0.001; Fig. 2A). However, only the highest concentration of
I-BET762 (1000 nM) reduced FCSTGF--induced prolifera-
tion in theASMcells fromboth nonsevere and severe asthmatic
patients (p 	 0.001; Fig. 2A). No effect upon cell viability was
seen at any concentration (data not shown).
I-BET762 (30–1000 nM) inhibited FCSTGF--induced
IL-6 release in a concentration-dependent manner by up to
27.2 3.3% in ASM cells isolated from healthy individuals (p	
0.001; Fig. 2B). In contrast, inhibition of FCSTGF--induced
IL-6 releasewas seenwith 1000 nM I-BET762 inASMcells from
both nonsevere and severe asthmatic patients (p 	 0.001; Fig.
2B). FCSTGF--induced CXCL8 release also had a different
pattern of suppression by I-BET762 compared with that seen
with IL-6 release. Suppression of FCSTGF--induced
CXCL8 release required an I-BET762 concentration of 300 nM
or greater in healthy ASM cells (p	 0.01), whereas significant
suppression of CXCL8 release was only seen at 1000 nM
I-BET762 in cells from nonsevere and severe asthmatics (p 	
0.001; Fig. 2C).
Effect of c-Myc Inhibition on FCSTGF--induced Prolifera-
tion and Inflammation—To determine whether the effects of
JQ1 result from targeting the pro-oncogenic transcription
factor, c-Myc, we analyzed the effect of the c-Myc inhibitor,
10058-F4, on proliferation and inflammation. Using a concen-
tration range used in previous studies (33, 34), we found that
concentrations higher than 75 M decreased ASM growth and
survival up to50% in theASMfromall three groups (p	 0.05)
(Fig. 3A). Therefore, we used the concentrations of 25 and 50
M to examine effects on proliferation. 25 M 10058-F4 inhib-
ited FCSTGF--induced proliferation in ASM cells from
nonsevere (70.0 10.7%) and severe asthmatics (52.9 20.7%)
(p 	 0.01 and p 	 0.001, respectively) (Fig. 3B). At the higher
concentration of 50 M, 10058-F4 inhibited proliferation in all
three groups (all p 	 0.001; Fig. 3B). 10058-F4 had no signifi-
cant effect upon either IL-6 or CXCL8 release (Fig. 3C).
Effect of Brd4 and c-MYC Knockdown with siRNA on
FCSTGF--induced ASM Proliferation and Inflammation—
To confirm the above results with pharmacological tools tar-
geting c-Myc and Brd4, we then transfected siRNAs into the
healthy ASM cells designed to target Brd4 and c-MYC. Inhibi-
tion of Brd4 with 300 nM of siRNA inhibited both the
FIGURE 2. I-BET762 suppresses FCS and TGF--induced cell proliferation
and cytokine release. A–C, the concentration-dependent effect of I-BET762
on FCS (2.5%) and TGF- (1 ng/ml)-induced cellular proliferation (A), IL-6
release (B), and CXCL8 release (C) after 8 days. Points represent means S.E.
from ASM cells from nine healthy (*), nonsevere asthma (#), and severe
asthma (‚) subjects. *, p 	 0.05; **, p 	 0.01; ***/###/, p 	 0.001
compared with FCSTGF--stimulated cells.
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FCSTGF--induced ASM proliferation and IL-6 release (p	
0.001) (Fig. 4, A and B). However, siRNA targeted inhibition of
c-MYC (300 nM) only resulted in a reduction in ASM prolifer-
ation (Fig. 4A) (p	 0.001) and not IL-6 release (Fig. 4B).
Effect of JQ1/SGCBD01 on c-MYC, p21WAF1, and p27kip1
mRNA in ASM—We next examined the effect of JQ1 upon
c-MYC mRNA expression. We found that FCSTGF-
increased the expression of c-MYC in ASM cells from severe
FIGURE 3. Inhibitionof c-Myc attenuates FCSandTGF--induced cell proliferationbut not IL-6 andCXCL8 release.A–C, concentration-dependent effect
of the c-Myc inhibitor (10058-F4, 0–150 M) on FCS (2.5%) and TGF- (1 ng/ml)-induced cell viability (A), cellular proliferation (B), and IL-6 and CXCL8 release
(C) fromASMcells fromhealthy (), nonsevere asthma (), and severe asthma (‚) subjects at 8days.Bars/points representmeansS.E. fromnineASMdonors
in each group. *, p	 0.05; **, p	 0.01; ***, p	 0.001 compared with untreated cells.
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asthmatics by 2.2 1.6-fold, with no effect on ASM cells from
normal and nonsevere asthmatics (p	 0.05) (Fig. 5A). Neither
JQ1 nor JQ1 had any effect on this increased expression (Fig.
5A).
We also examined the effect of JQ1 upon p21WAF1 and
p27kip1 mRNA levels. We have previously demonstrated that
these cyclin inhibitors are crucial for ASM proliferation (7). As
previously seen, we showed a decrease in p21WAF1 mRNA
expression following FCSTGF- stimulation in theASMcells
from the severe asthmatics by 0.53 0.32-fold (p	 0.01) (Fig.
5B). There was a decrease in p27kip1 expression in both the
nonsevere (0.46 0.30, p	 0.05) and severe (0.29 0.31, p	
0.01) ASM cells (Fig. 5C). JQ1 recovered the expression of
both p21WAF1 in the severe asthmatics (p	 0.05) (Fig. 5B) and
p27kip1 in both the nonsevere and severe asthma subjects back
to basal levels (both p	 0.05) (Fig. 5C).
Effect of JQ1/SGCBD01 on IL6 mRNA in ASM and upon
Binding of Brd4 to the IL6 Gene Promoter—To determine
whether BET regulation of IL-6 release occurred at the tran-
scriptional level, we analyzed the expression of IL6 mRNA at
24 h poststimulation. Both FCS and TGF- alone induced a
small increase in IL6 mRNA in all cell types, although the
responsewas greater in cells from severe asthmatics (p	 0.001)
(Fig. 6, A, C, and E).
FCSTGF- in combination induced a significant induction
of IL6mRNA in cells isolated from healthy individuals (14.3
8.9, p	 0.01) (Fig. 6A), nonsevere asthmatics (20.6 12.6, p	
0.01) (Fig. 6C), and severe asthmatics (43.7  27.4, p 	 0.01)
(Fig. 6E). There was a greater response in cells from severe
asthmatics compared with normal (p	 0.01).When these cells
were pretreated with JQ1 (1000 nM) for 1 h before
FCSTGF- stimulation, there was almost complete suppres-
sion of IL6mRNA expression in all patient groups (p	 0.001)
FIGURE 4. Effect of targeting of Brd4 and c-MYC with siRNAs on FCS and
TGF--induced cell proliferation and IL-6 release. ASM cells from healthy
subjects were transfectedwith siRNAs designed to target Brd4 and c-MYC, or
a negative (Neg) control (100 nM), before being stimulated with FCS (2.5%)
and TGF- (1 ng/ml). Cellular proliferation (A) and IL-6 release (B) were mea-
sured at 8 days. Bars represent means S.E. from nine ASM donors. ***, p	
0.001 compared with stimulated cells.
FIGURE 5. Effect of JQ1/SGCBD01 on FCS and TGF--induced c-MYC,
p21WAF1 and p27kip1 mRNA expression. A–C, effect of JQ1 and JQ1
pretreatment (both at 1 M) on FCS (2.5%) and TGF- (1 ng/ml)-induced
c-MYC, (A), p21WAF1 (B), and p27kip1 (C) mRNA expression in ASM cells from
healthy, nonsevere asthmaand severe asthmasubjects at 24h.Bars represent
meansS.E. fromnineASMdonors in eachgroup. *,p	0.05; **,p	0.01; ***,
p 	 0.001 compared with unstimulated cells. , p 	 0.05; , p 	 0.001
compared with FCSTGF--stimulated cells.
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(Fig. 6, A, C, and E). The negative enantiomer, JQ1, had no
effect upon the transcription of IL6.
We used ChIP analysis to investigate the binding of Brd4 to
the IL6 promoter region. ASM cells were serum-starved for
24 h before being stimulated with FCS (2.5%) and/or TGF- (1
ng/ml) for 24 h. In some cases, cells were pretreated for 1 hwith
either 1000 nM JQ1 or JQ1. There was more Brd4 associated
with the IL6 gene promoter in the ASM cells from the severe
asthmatics compared with controls at baseline (data not
shown). Although the ChIP experiments did not show signifi-
cance, there was a trend for increased Brd4 association with the
IL6 promoter with FCSTGF- treatment in the healthy sub-
jects andnonsevere asthmatics, whichwas reduced by JQ1but
not by JQ1 (Fig. 6, B and D). Furthermore, stimulation of
severe asthmatic ASM cells with FCSTGF- reduces fold
enrichment of IL6. The addition of JQ1 to these same cells
increases this reduction in enrichment, and JQ1 has no effect
(when comparing to the Cells  [FCSTGF-] bar). Impor-
tantly, we were unable to show clear evidence for c-Myc asso-
ciationwith the IL6promoters inASMcells fromhealthy subjects
orasthmatic subjects comparedwithcontrol input samplesandno
evidence for enhanced c-Mycbinding following stimulation of the
cells with FCS (2.5%) and/or TGF- (1 ng/ml) in the presence or
absence of JQ1 or JQ1 (data not shown).
Effect of JQ1/SGCBD01 on CXCL8 mRNA in ASM and upon
Binding of Brd4 to the IL8 Gene Promoter—Similarly to IL-6,
both FCS and TGF- alone induced a small increase in IL8
mRNA in all cell types, although the response was always
greater in cells from severe asthmatics (p	 0.001) (Fig. 7, A, C,
and E).
FIGURE 6. JQ1/SGCBD01 attenuates FCS and TGF--induced IL6mRNA expression and decreases association with IL6 promoters. A, C, and E, effect of
JQ1 and JQ1 pretreatment (both at 1M) on FCS (2.5%) and TGF- (1 ng/ml)-induced IL6mRNA expression in ASM cells fromhealthy (A), nonsevere asthma
(C), and severe asthma (E) subjects at 24 h. Bars representmeans S.E. fromnine ASMdonors in each group. B,D, and F, effect of JQ1 and JQ1 on FCS (2.5%)
and TGF- (1 ng/ml)-induced Brd4 IL6promoter bindingmeasured by ChIP in ASMcells fromhealthy (B), nonsevere asthma (D), and severe asthma (F) subjects
at 24 h. Bars representmeans S.E. from three ASMdonors in each group. *, p	 0.05; **, p	 0.01; ***, p	 0.001 comparedwith unstimulated cells., p	
0.001 compared with FCSTGF--stimulated cells.
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FCSTGF- in combination induced a significant induction
of IL8 mRNA in cells isolated from healthy individuals (7.0 
5.4, p	 0.05), nonsevere asthmatics (15.6 8.9, p	 0.01), and
severe asthmatics (33.4  21.4, p 	 0.01) (Fig. 7, A, C, and E).
There was a greater response in cells from severe asthmatics
compared with normal (p	 0.01). When these cells were pre-
treated with JQ1 (1000 nM) for 1 h before FCSTGF- stim-
ulation, there was almost complete suppression of IL8 mRNA
expression in all patient groups (p	 0.001) (Fig. 7,A,C, and E).
The negative enantiomer, JQ1, had no effect upon the tran-
scription of IL8.
Once again, we used ChIP analysis to investigate the binding
of Brd4 to the IL8 promoter region. Similarly to IL6, there was
more Brd4 associated with the IL8 gene promoter in the ASM
cells from the severe asthmatics compared with controls at
baseline (data not shown). Therewas a trend for increased Brd4
associationwith the IL8 promoter with FCSTGF- treatment
in all subjects, which was reduced by JQ1 but not JQ1 (Fig. 7,
B,D, and F). There was no clear evidence for c-Myc association
with the IL8 promoter in ASM cells from any subjects com-
paredwith control input samples and no evidence for enhanced
c-Myc binding following stimulation of the cells with FCS
(2.5%) and/or TGF- (1 ng/ml) in the presence or absence of
JQ1 or JQ1 (data not shown).
DISCUSSION
We have shown that the BET mimics JQ1/SGCBD01 and
I-BET762 inhibited FCSTGF--induced cell proliferation
and inflammation in ASM cells from healthy and asthmatic
individuals. The concentrations required to inhibit prolifera-
tion were higher in cells from nonsevere and severe asthmatics,
indicating that there is an innate resistance of asthmatic cells to
FIGURE 7. JQ1/SGCBD01 attenuates FCS and TGF--induced IL8mRNA expression and decreases association with IL8 promoters. A, C, and E, effect of
JQ1 and JQ1 pretreatment (both at 1M) on FCS (2.5%) and TGF- (1 ng/ml)-induced IL8mRNA expression in ASM cells fromhealthy (A), nonsevere asthma
(C), and severe asthma (E) subjects at 24 h. Bars representmeans S.E. fromnine ASMdonors in each group. B,D, and F, effect of JQ1 and JQ1- on FCS (2.5%)
and TGF- (1 ng/ml)-induced Brd4 IL8 promoter bindingmeasured byChIP in ASMcells fromhealthy (B), nonsevere asthma (D), and severe asthma (F) subjects
at 24 h. Bars represent means  S.E. from three ASM donors in each group. *, p 	 0.05; **, p 	 0.01 compared with unstimulated cells. , p 	 0.001
compared with FCSTGF--stimulated cells.
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the effect of these BET mimics. Inhibition of c-Myc affected
ASM proliferation but not IL-6 or CXCL8 production. JQ1/
SGCBD01 reduced the association of Brd4 to the IL6 and IL8
promoters, thereby modulating their transcription.
We showed that BET proteins in primary ASM cells are
important in controlling ASM cell proliferation both in healthy
and asthmatic cells. Previous studies have mainly focused on
cancerous cell lines, where JQ1/SGCBD01 inhibited cellular
proliferation of NUTmidline carcinoma (35), lung cancer cells
(36), acute myeloid leukemia cells (37), and a human leukemic
cell line (UT7) (38). This mechanism is documented to occur
via a decrease in either c-Myc expression or c-Myc association
with a number of proliferative gene promoters. c-Myc is a reg-
ulatory transcription factor that regulates cell growth, and
deregulation of c-Myc in cancer contributes to proliferation,
tumorigenesis, and resistance to apoptosis. Furthermore,
amplification of c-Myc is one of the most common genetic
alterations in cancer genomes (39). Although we show that
inhibition of c-Myc inhibits proliferation, we saw no effect of
JQ1/SGCBD01 upon the induced expression of c-Myc expres-
sion by FCSTGF, demonstrating that the effect of JQ1
upon c-Myc expression seen in cancerous cells and nonprimary
cells is different from that seen in noncancerous asthmatic
ASM cells.
Our results provide evidence that the effect of JQ1/
SGCBD01 and I-BET762 is independent of the induction of
c-Myc, as has been demonstrated in glioblastomas where JQ1/
SGCBD01 had a minimal effect upon c-Myc expression. JQ1/
SGCBD01 had a significant effect upon p21WAF1 expression,
returning it to basal levels (35). We have previously shown that
primary ASM proliferation is under the control, at least in part,
of p21WAF1 and p27kip1 (4, 6). Here we show that JQ1/
SGCBD01 may mediate its response in asthmatic ASM by
returning the reduced expression of these cyclin inhibitors to
basal levels. The release of IL-6 andCXCL8 fromASMcells was
not affected by pharmacological inhibition of c-Mycwhich cor-
respondedwith the failure to showmarked physical association
of c-Myc to the IL6 and IL8 promoters.
We also demonstrate that BET bromodomain mimics JQ1/
SGCBD01 and I-BET762 inhibited FCSTGF--induced
release and gene expression of IL-6 and CXCL8 in ASM cells
from all three groups of subjects. However, these inhibitors
were less effective onASMcells frompatientswith asthma.Our
chromatin immunoprecipitation data show that there was a
greater amount of enrichment of Brd4 at the IL6 and IL8 pro-
moters at baseline in ASM cells from severe asthma compared
with nonasthmatics subjects. FCSTGF- increased Brd4
binding to the IL6 and IL8 promoters in the controls but only
the IL8 promoter in the ASM cells isolated from severe asth-
matics. JQ1/SGCBD01 did not significantly inhibit this enrich-
ment of either the IL6 or the IL8 promoters.
Increased Brd4 binding at baselinemay allow greater IL6 and
IL8 gene expression, explaining the increased inflammation in
severe asthmatics compared with controls. Thus, inhibition of
Brd4 binding to the gene promoters may explain the mecha-
nism of action of JQ1/SGCBD01 and by extension of I-BET762
in inhibiting cytokine gene expression. The differential effect of
JQ1/SGCBD01 and I-BET762 on IL-6 and CXCL8 expression
and on basal Brd4 promoter associationmay reflect differences
in the underlyingmechanisms controlling these genes, with IL6
expression being regulated by Brd4 proteins at a paused pro-
moter, whereas IL8 transcription requires Brd4 recruitment
before transcription can occur. Promoter pausing is an increas-
ingly identified as a key regulatory step in the transcription of
rapidly transcribed genes, including those involved in stress
and inflammation (40, 41). Brd4 may be bound to the IL6 pro-
moter region prior to the TGF/FCS signal being received,
allowing more rapid response to stimuli. Brd4 has previously
been associated with recruitment of the pause release factor
p-TEFB (42), andwe therefore believe that the role of transcrip-
tional pausing in the regulation of inflammation will make an
interesting area of future research.
Similar findings have been reported with both JQ1/
SGCBD01 and I-BET762. In murine bone marrow-derived
macrophages exposed to bacterial endotoxin, I-BET762 inhib-
ited the expression of pro-inflammatory cytokines such as
IL-1, IL-6, IL-12, CXCL9, and CCL2, and I-BET762 dis-
placed the BET proteins Brd2, Brd3, and Brd4 from the IL6
promoter (23). I-BET762 was also shown to rescue mice from
endotoxin-induced death. Similar results using JQ1/SGCBD01
were obtained for the endotoxin-induced production of IL-6
and TNF- in mousemacrophages. In these experiments, Brd2
and c-Myc were shown to be physically associated with the
promoter regions of these inflammatory genes (26). Both
I-BET762 and JQ1/SGCBD01 have been reported to inhibit the
release of IL-6 from human lung fibroblasts and their prolifer-
ation induced by TGF-, by reducing Brd2 and Brd4 associa-
tion with growth factor-responsive genes and enhanced tran-
scription of these genes (43). The differential effect of JQ1/
SGCBD01 and I-BET762 on IL-6 and CXCL8 expression and
on basal Brd4 promoter association may reflect differences in
the underlying mechanisms controlling these genes, with IL6
expression being regulated by Brd proteins at a paused pro-
moter, whereas IL8 transcription requires Brd recruitment
before transcription can occur.
A higher concentration of both JQ1/SGCBD01 and
I-BET762 was needed to inhibit proliferation and IL-6 and
CXCL8 release from cells from patients with asthma compared
with nonasthmatic subjects. Asthmatic ASM cells demonstrate
a greater degree of proliferation and release of cytokines such as
IL-6 when exposed to FCSTGF- compared with ASM cells
from nonasthmatic subjects (4, 15). The increased Brd4 associ-
ation observed in the asthmatic samples (and possible tran-
scriptional pausing of the inflammatory gene promoters) may
explain the higher levels of transcription of IL6 and IL8 after
stimulation of the cells (Figs. 6 and 7). Thismay also explain the
need for a greater amount of the BET mimics to produce the
same effect as in nonasthmatic ASM cells. Part of the explana-
tion could lie with the greater association of Brd4 to the IL6
promoter observed in severe asthmatics at baseline compared
with controls at baseline. Although not significant, the binding
of Brd4 to the promoter regions of IL6 and IL8 increased when
the cells were stimulated by FCSTGF-, an effect that was
prevented by pretreatment of the cells with JQ1/SGCBD01.
The relative insensitivity of ASM cells from asthma patients
to the BET mimics reminds us of the similar insensitivity
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observed with corticosteroids (4, 15). The basis for corticoste-
roid insensitivity in asthmamay bemultifactorial (44). A lack of
recruitment of histone deacetylase 2 to the RNA polymerase
compatible with histone deacetylase activity being reduced in
peripheral blood mononuclear cells and alveolar macrophages
frompatientswith asthmahas been proposed (18, 45). The gene
promoters in cells from asthma versus nonasthma may have an
enhanced acetylation status that may in part account for the
reduced sensitivity to BET mimics in these cells.
BET bromodomain mimics can inhibit both aberrant ASM
cell proliferation and pro-inflammatory cytokine production
from cells from patients with asthma including severe asthma.
Interestingly, a pharmaceutical company, Tensha Therapeu-
tics, is currently in phase I clinical trials evaluating a derivative
of JQ1/SGCBD01 (TEN-010) in patients with solid tumors (46),
and although local delivery of these compounds has yet to be
studied, systemic administration of JQ1/SGCBD01 signifi-
cantly inhibits inflammatory cytokine expression in diseased
gingival tissues (47) and demonstrates no affect upon systemic
blood pressure (7). These compounds may therefore be effec-
tive in reducing features of airway remodeling in severe asthma,
which often forms the basis of chronic airflow obstruction and
greater inflammatory responses that are often insensitive to the
effects of anti-inflammatory agents such as corticosteroids.
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